en · de · es · fr · pt
sr9009-notes.peptides6088.com › Guide › Identity, Handling, And Regulation — Evidence Review

Identity, Handling, And Regulation — Evidence Review

By Editorial Desk · published 2025-09-02 · last reviewed 2025-09-29 · Guide

REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-09-29. Where a claim depends on a specific study, the study is described rather than over-claimed.

Identity, Handling, and Regulation

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

SR9009 Handling and Quality Control

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

Sr9009 at a glance

PropertyValueNotes
AppearanceWhite to off-white solidVisual inspection is not sufficient for identity.
SolubilitySoluble in DMSO and ethanolLow solubility in water.
Typical storage-20 °C, desiccated, darkProtect from repeated temperature changes.
Common analytical methodLC-MS or HPLC-UVReference standard required for comparison.
Common synonymsSR9009; Stenabolic; REV-ERB agonistVendor naming may vary.

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

Related pages on this site

Detection, Regulation, and Misconceptions

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Reference notes

The governments of these regions, which had their origins in the juntas of 1810, and even moderates there, who had entertained a reconciliation with the crown, now saw the need to separate from Spain if they were to protect the reforms they had enacted.

Additionally, the heavy alkaline earth metals calcium, strontium, and barium, as well as the divalent lanthanides europium and ytterbium, are pale yellow, though the colour is much less prominent than it is for caesium. Their lustre tarnishes rapidly in air due to oxidation.

his work on insect embryology and metamorphosis, and the embryology of Symphyla; his experimental studies on the innervation of skeletal muscle and the functional relation of the sympathetic system to muscle (Orbeli effect); his histological work on muscle, especially the helicoidal structure of the striated muscle fibre; and other research concerning: histology of the neurosynapse; innervation of teeth; chemical transmission at dorsal root nerve endings. He was appointed to a Chair of Zoology at the University of Melbourne in 1948 which he held until his death, and became a full Professor in 1948. Oscar Tiegs served as Dean of the Faculty of Science the University of Melbourne from 1950 to 1952. In 1951 Professor Wilfred Agar died and Oscar Tiegs became Professor and took over as head of the Melbourne University Zoological Department. Others state that Oscar Tiegs took the Chair of Zoology at the University of Melbourne in 1948 upon the retirement of Professor Wilfred Agar. In 1954 he took sabbatical leave and travelled overseas a second time supported by a British Council travel grant. This second trip provided Oscar Tiegs with the opportunity to be formally admitted to the Royal Society, after being elected as a Fellow 10 years earlier. While in England he also chaired a session of the Sixth Commonwealth Entomological Conference. He also delivered a series of three lectures on the flight muscles of insects at the University of London during March 1954

== History == Gordon C. Sharp first described mixed connective tissue disease (MCTD) in 1972 as an entity with mixed features of systemic sclerosis (SSc), systemic lupus erythematosus (SLE), polymyositis/dermatomyositis (PM/DM), and rheumatoid arthritis (RA) along with an elevated level of high-titre anti-U1small nuclear (sn) anti-ribonucleoprotein (anti-RNP) antibodies.

Sources: en.wikipedia.org

Notes from published material

On paper, these edicts had to be ratified by the Assembly at its next session to remain in effect, but such ratification was usually a formality. The liberal democratic character of the Hungarian parliament was reestablished with the fall of the Iron Curtain and the end of the communist dictatorship in 1989. The Assembly's constitutional designation as the highest organ of power was retained after the end of communism and removed only by the Fidesz-drafted Fundamental Law of Hungary in 2012.

Ancient habitation areas, longhouses, crop terraces, roads as the Inca road system, cemeteries, hypogeums and necropolises are all part of the architectural heritage of indigenous peoples. Some prominent indigenous structures are the preceramic and ceramic archaeological site of Tequendama, Tierradentro (a park that contains the largest concentration of pre-Columbian monumental shaft tombs with side chambers), the largest collection of religious monuments and megalithic sculptures in South America, located in San Agustín, Huila, Lost city (an archaeological site with a series of terraces carved into the mountainside, a net of tiled roads, and several circular plazas), and the large villages mainly built with stone, wood, cane, and mud. Architecture during the period of conquest and colonization is mainly derived of adapting European styles to local conditions, and Spanish influence, especially Andalusian and Extremaduran, can be easily seen. When Europeans founded cities two things were making simultaneously: the dimensioning of geometrical space (town square, street), and the location of a tangible point of orientation. The construction of forts was common throughout the Caribbean and in some cities of the interior, because of the dangers posed to Spanish colonial settlements from English, French and Dutch pirates and hostile indigenous groups. Churches, chapels, schools, and hospitals belonging to religious orders have a great urban influence. Baroque architecture is used in military buildings and public spaces.

== History == AbbVie was formed in 2012 as a corporate spin-off from Abbott Laboratories. It became a public company in January 2013. In January 2014, the company acquired ImmuVen, a startup incubated at the University of Illinois Urbana-Champaign and focused on biotherapeutics to treat cancer, infectious disease, and autoimmune disorders. In September 2014, AbbVie and Infinity Pharmaceuticals entered into a collaboration to develop and commercialize duvelisib, Infinity's PI3K inhibitor for the treatment of patients with cancer. On the same day, AbbVie and Calico entered into a research and development (R&D) collaboration intended to discover, develop and bring to market new therapies for patients with aging-associated diseases including neurodegeneration and cancer. California Life Company, operating as Calico, is an Alphabet Inc. subsidiary focused on aging and age-related diseases, and led by former Genentech chairman and CEO of Arthur D. Levinson and former Genentech EVP and chief medical officer Hal V. Barron (who subsequently left the company). In October 2014, AbbVie ended its efforts to acquire Shire, which would have been one of the largest mergers and acquisitions (M&A) deals of that year and one of the largest tax inversions in history, due to changes in the US tax code by the US Treasury; AbbVie had to pay a $1.6 billion breakup fee. In May 2015, AbbVie acquired oncology firm Pharmacyclics and its treatment for blood cancers, ibrutinib; AstraZeneca had also been bidding to acquire Pharmacyclics.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 usually analyzed?

Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.

What storage conditions are typical?

The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.

Is SR9009 legal to purchase?

Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.

How is SR9009 detected in samples?

Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.

Network